Swine Flu News and Research

RSS

Swine Flu or influenza A (H1N1) is a new flu virus of swine origin that first caused illness in Mexico and the United States in March and April, 2009. It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread, mainly through the coughs and sneezes of people who are sick with the virus, but it may also be spread by touching infected objects and then touching your nose or mouth. Novel H1N1 infection has been reported to cause a wide range of flu-like symptoms, including fever, cough, sore throat, body aches, headache, chills and fatigue. In addition, many people also have reported nausea, vomiting and/or diarrhea.

Government closely monitors swine flu vaccine

The government is closely monitoring the safety of the new H1N1 swine flu vaccine amid people's concerns.

19 Oct 2009

Asthma is the most common underlying condition associated with H1N1 Swine Flu: CDC Report

Cannabis Science Inc., an emerging pharmaceutical cannabis company, notes a report by epidemiologists at the Centers for Disease Control and Prevention (CDC) saying that, among people hospitalized with severe cases of the pandemic strain of H1N1 Swine Flu, asthma is by far the most common underlying condition associated with he disease.

19 Oct 2009

Survey reports patients' concern about the safety and access to flu vaccines

Although some parents may be lukewarm to the H1N1 vaccination, Lakeside Community Healthcare www.LakesideCommunityHealthcare.com, one of Southern California's largest integrated, comprehensive healthcare organizations, reports broader patient concern about both the safety of and access to the vaccine.

15 Oct 2009

Hospital visitation policy to reduce the spread of H1N1 flu

Due to the severity of the H1N1 flu and its potential to spread to patients, children and expectant mothers, Lucile Packard Children’s Hospital and Stanford Hospital & Clinics announced today that effective Monday, October 19, 2009, both hospitals will no longer allow non-patient visitors or family members under the age of 16 inside the hospitals.

15 Oct 2009

UT Southwestern Medical Center awarded $15.7M NIH contract to develop a new virus database

The National Institutes of Health has awarded a $15.7 million contract to UT Southwestern Medical Center and Northrop Grumman Corp. to develop an open-access national online database and analysis resource center that will help scientists study and combat viruses such as those that cause hepatitis, encephalitis, smallpox, acute respiratory distress and dengue fever, as well as newly emerging pathogenic viruses.

15 Oct 2009

Human populations may have some level of existing immunity to the pandemic H1N1 influenza, say researchers

University of California, Davis, researchers studying the 2009 H1N1 influenza virus, formerly referred to as "swine flu," have identified a group of immunologically important sites on the virus that are also present in seasonal flu viruses that have been circulating for years. These molecular sites appear to result in some level of immunity to the new virus in people who were exposed to the earlier influenza viruses.

15 Oct 2009

Required flu vaccines for New York health workers draws criticism

The New York Civil Liberties Union is criticizing a regulation that requires hundreds of thousands of state health workers to get both seasonal and swine flu vaccinations. Critics say it violates workers' right to decide their own medical treatment.

15 Oct 2009

Surveillance of travel-related illness helps to detect and respond to H1N1 influenza

Because pandemics unfold in unpredictable ways, surveillance of travel-related illness is among the most powerful tools health officials and doctors can use to detect and respond to new pathogens like the novel H1N1 influenza, says the physician who heads the University of Alabama at Birmingham (UAB) Travelers' Clinic.

15 Oct 2009

Biosante Pharmaceuticals, Cell Genesys successfully complete merger

BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc., today announced the successful completion of their previously announced merger of Cell Genesys with and into BioSante, with BioSante as the surviving company, under which BioSante now has acquired all of the outstanding shares of Cell Genesys common stock.

15 Oct 2009

Atlantic examines flu vaccine, antiviral skepticism

As countries around the world roll out H1N1 (swine flu) virus vaccine campaigns, the Atlantic examines, "[W]hat if everything we think we know about fighting influenza is wrong?"

15 Oct 2009

Richmont Sciences to market PURE’s antimicrobial SDC disinfectants

PURE Bioscience announced that it has expanded its business strategy through an alliance with the Dallas-based sales and marketing team Richmont Sciences, LLC, which will begin actively selling PURE’s revolutionary new antibacterial, antiviral and antifungal hard surface disinfectant and its active ingredient.

14 Oct 2009

Sinovac Biotech announces receipt of Panflu vaccine distribution approval in Hong Kong

Sinovac Biotech Ltd., a leading developer and provider of vaccines in China, announced today that its wholly-owned subsidiary, Sinovac Biotech (Hong Kong) Ltd, has received the Certificate of Approval to distribute Panflu(TM) (H5N1), its H5N1 (bird flu) pandemic influenza vaccine, in Hong Kong. The certificate is valid through September 13, 2014 and thereafter will be renewable for periods of five years at a time, subject to payment of the registration fee.

14 Oct 2009

Inovio Biomedical's proprietary DNA vaccine development platform introduced

Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, president and CEO, presented at the invitation-only World Knowledge Forum being held in Seoul, South Korea.

14 Oct 2009

Do not underestimate the serious impact of the H1N1 virus, say researchers

A research team has warned medical experts in the Northern Hemisphere not to underestimate the serious impact of the H1N1 (Swine flu) virus with a new report showing that many patients who were critically ill with the virus required prolonged life support treatment with heart-lung machines.

14 Oct 2009

New Ultra Sensitive facemasks to protect against seasonal and swine flu

BIOSAFE, Inc., a company that manufactures and sells a novel antimicrobial polymer, has announced that they are launching in specific markets outside the United States through a unique facemask treated with BIOSAFE(®). Crosstex' new BIOSAFE-treated Ultra Sensitive facemasks begin to reduce microorganisms such as MRSA, VRE, and Staph immediately upon contact, and have further proven to be effective against Influenza A strains such as seasonal flu and the novel H1N1 virus.

14 Oct 2009

Studies examine H1N1 treatment, outcome differences in Mexico, Canada

New studies suggest that "[d]eveloping countries with limited access to advanced health-care facilities may be in for a rough ride with swine [H1N1] flu and even countries with high-tech ICUs may find themselves pushed to the limit as their hospitals struggle to save gravely ill H1N1 patients," the Canadian Press reports.

14 Oct 2009

NIH awards $2.2m grant to Smiths Detection to develop a test for multiple types of influenza

Smiths Detection today announces the award of a $2.2m, two-year grant from the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health (NIH), to develop a test for multiple types of influenza.

14 Oct 2009

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

People with psoriasis and/or psoriatic arthritis who are taking biologic or non-biologic immunosuppressive medications should receive the inactived forms of both seasonal influenza and H1N1 (swine flu) vaccines as soon as possible, according to a recommendation from the National Psoriasis Foundation.

13 Oct 2009

HAAN provides swine flu tips

While Americans anxiously await the arrival of the H1N1 Flu Vaccine in their area, many are seeking new methods to try to keep their homes germ free and their families healthy during this flu season.

13 Oct 2009

Fully-insured members of Guardian to receive 100% coverage of the administrative cost of H1N1 vaccine

The Guardian Life Insurance Company of America (Guardian), one of the largest mutual life insurers and a leading provider of employee benefits for small and mid-sized companies, today announced that it will cover 100% of the cost associated with the administration of the H1N1 vaccine for employees and their eligible dependents enrolled in a fully-insured Guardian medical plan.

13 Oct 2009

Swine Flu News and Research

Further Reading

Government closely monitors swine flu vaccine

Asthma is the most common underlying condition associated with H1N1 Swine Flu: CDC Report

Survey reports patients' concern about the safety and access to flu vaccines

Hospital visitation policy to reduce the spread of H1N1 flu

UT Southwestern Medical Center awarded $15.7M NIH contract to develop a new virus database

Human populations may have some level of existing immunity to the pandemic H1N1 influenza, say researchers

Required flu vaccines for New York health workers draws criticism

Surveillance of travel-related illness helps to detect and respond to H1N1 influenza

Biosante Pharmaceuticals, Cell Genesys successfully complete merger

Atlantic examines flu vaccine, antiviral skepticism

Richmont Sciences to market PURE’s antimicrobial SDC disinfectants

Sinovac Biotech announces receipt of Panflu vaccine distribution approval in Hong Kong

Inovio Biomedical's proprietary DNA vaccine development platform introduced

Do not underestimate the serious impact of the H1N1 virus, say researchers

New Ultra Sensitive facemasks to protect against seasonal and swine flu

Studies examine H1N1 treatment, outcome differences in Mexico, Canada

NIH awards $2.2m grant to Smiths Detection to develop a test for multiple types of influenza

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

HAAN provides swine flu tips

Fully-insured members of Guardian to receive 100% coverage of the administrative cost of H1N1 vaccine

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News